Description: Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Home Page: icosavax.com
ICVX Technical Analysis
1616 Eastlake Avenue East
Seattle,
WA
98102
United States
Phone:
206 737 0085
Officers
| Name | Title |
|---|---|
| Mr. Adam K. Simpson | Pres, CEO, Co-Founder & Director |
| Mr. Thomas Joseph Russo C.F.A. | Chief Financial Officer |
| Ms. Elizabeth Bekiroglu | Gen. Counsel & Corp. Sec. |
| Mr. Neil King Ph.D. | Chair of Scientific Advisory Board & Co-Founder |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board |
| Dr. Charles E. Richardson Ph.D. | Sr. VP of Technical Operations |
| Mr. Douglas A. Holtzman M.P.H., Ph.D. | Chief Scientific Officer |
| Ms. Lori Stewart | VP of People & Culture |
| Mr. Niranjan Kanesa-thasan M.D. | Chief Medical Officer |
| Dr. Ami Shah Brown MPH, Ph.D. | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 77.2727 |
| Price-to-Book MRQ: | 1.5772 |
| Price-to-Sales TTM: | 153.3126 |
| IPO Date: | 2021-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |